Navigation Links
Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

CAMBRIDGE, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 a.m. ET in the Park Avenue Suite Center/North Room at the Waldorf-Astoria Hotel in New York, NY.

The live and archived webcasts of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com or directly linking to http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=131556&eventID=1752370. (Due to the length of URL, please cut and paste into browser). Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Gain recognition for leadership and ... the biotech industry. Nominations are now being accepted ... you by the Bio Supply Management Alliance ... management professionals for the past 7 years. , ... Biotech industry – Manufacturers, Service Providers, Material Suppliers, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... human evolution follows a progressive trajectory is one of ... is often expressed in popular media by showing cavemen ... a notable exception). But is this assumption correct? ... In a paper published in the ...
... stop the spread of a deadly fungus that is threatening ... a new mathematical model. , White-nose syndrome, which is estimated ... year period, is probably caused by a newly discovered cold-adapted ... WNS is passed from bat to bat and concludes that ...
... and warms the world,s oceans with carbon emissions, the harder ... That,s the blunt message from a major new study ... and global warming will combine with local impacts like overfishing ... when they are struggling to survive. Modelling by a ...
Cached Biology News:Earliest humans not so different from us, research suggests 2Earliest humans not so different from us, research suggests 3Culling can't control deadly bat disease 2Acid oceans demand greater reef care 2
... a multitasking application capable of dynamic scheduling, ... operation of lab automation workcells easy for ... modification by programmers. • Users ... flowchart. If you can build a flowchart, ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
... digital microscope and camera system that does ... adjustment or software installation. Built on Nikon's ... simplicity and advanced technology for users of ... of a macro image and a micro ...
Biology Products: